$1.15
4.96% yesterday
Nasdaq, Apr 03, 09:49 pm CET
ISIN
US28658R1068
Symbol
CLYM
Sector
Industry

Eliem Therapeutics Inc Stock price

$1.15
-0.20 14.81% 1M
-3.95 77.45% 6M
-0.65 36.11% YTD
-1.62 58.48% 1Y
-7.20 86.23% 3Y
-14.75 92.77% 5Y
-14.75 92.77% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.06 4.96%
ISIN
US28658R1068
Symbol
CLYM
Sector
Industry

Key metrics

Market capitalization $77.60m
Enterprise Value $-72.79m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 4.68
P/B ratio (TTM) P/B ratio 0.37
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-27.02m
Free Cash Flow (TTM) Free Cash Flow $-15.56m
Cash position $150.92m
EPS (TTM) EPS $-2.13
Short interest 2.38%
Show more

Is Eliem Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Eliem Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Eliem Therapeutics Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Eliem Therapeutics Inc:

Buy
100%

Financial data from Eliem Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 15 15
38% 38%
-
- Research and Development Expense 12 12
25% 25%
-
-27 -27
33% 33%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -27 -27
33% 33%
-
Net Profit -74 -74
110% 110%
-

In millions USD.

Don't miss a Thing! We will send you all news about Eliem Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Eliem Therapeutics Inc Stock News

Neutral
GlobeNewsWire
3 days ago
WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors.
Neutral
GlobeNewsWire
8 days ago
WELLESLEY, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at the 24th Annual Needham Healthcare Conference being held virtually April 7-10, 2025.
Neutral
GlobeNewsWire
10 days ago
Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE)
More Eliem Therapeutics Inc News

Company Profile

Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its clinical-stage candidates are ETX-810 and ETX-155. ETX-810 is a novel palmitoylethanolamide (PEA) prodrug initially being developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and pain associated with lumbosacral radiculopathy. ETX-155 is a neurosteroid GABAA receptor positive allosteric modulator (PAM) initially being developed for major depressive disorder (MDD), perimenopausal depression (PMD) and focal onset seizures. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Redmond, WA.

Head office United States
CEO Aoife Brennan
Employees 18
Founded 2018
Website www.climbbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today